Search

OBJECTIVE: To characterize Costa Rican clinical isolates of the T. mentagrophytes complex to determine the predominant species and their susceptibility pattern. MATERIALS AND METHODS: An experimental study was conducted to typify and determine the antifungal susceptibility of isolates from the T. mentagrophytes complex, obtained from skin and nail samples, done from 2019 to 2020. Molecular typification was performed by sequencing the ITS region. Broth microdilution M38-A method, as described by the Clinical Laboratory and Standards Institute, was employed to determine the antifungal susceptibility patterns of the isolates. RESULTS: Fifteen isolates were analyzed and all were identified as Trichophyton interdigitale. The MIC50 and MIC90 were 0.13 and 0.50 μg/mL for amorolfine, 0.25 and 0.50 μg/mL for bifonazole, 0.50 and 5.60 μg/mL for ciclopirox, 0.25 and 6.70 μg/mL. for itraconazole, 32 and 89.60 μg/mL for fluconazole, and 0.13 and 0.35 μg/mL for terbinafine respectively. CONCLUSIONS: In the present study, only T. interdigitale was identified among the species belonging to T. mentagrophytes complex, which demonstrates a person-toperson transmission. All isolates were susceptible to amorolfine, bifonazole, ciclopirox and terbinafine. However, the majority exhibited resistance to itraconazole and fluconazole. [ABSTRACT FROM AUTHOR]

BACKGROUND: Scopularíopsis sp is a causal agent of onychomycosis; however, its therapeutical regimen hasn't been established. OBJECTIVE: To evaluate the in vitro activity of fluconazole, itraconazole, terbinafine, ciclopirox and amorolfine against clinical isolates of Scopulariopsis sp. MATERIAL AND METHOD: An experimental study was done to assess the in vitro susceptibility of 11 clinical isolates of Scopulariopsis sp using the microdilution method M38-A, as described by the Clinical Laboratory Standards Institute, from August to December 2017. The final concentrations were: 0.13-64 pg/mL for amorolfine and terbinafine, 0.06-32 pg/mL for ciclopirox, 0.03-16 pg/mL for itraconazole and 0.25- 128 pg/mL for fluconazole. RESULTS: The MICS0 and MICgo were 0.13 and 24 pg/mL for amorolfine, 2 and 4 pg/mL for terbinafine, 4 and 8 pg/mL for ciclopirox, > 16 y > 16 pg/mL for itraconazole and > 128 and> 128 pg/mL for fluconazole, respectively. CONCLUSIONS: Amorolfine and terbinafine exhibited the highest antifungal activity and fluconazole the lowest against clinical isolates of Scopulariopsis sp. [ABSTRACT FROM AUTHOR]

BACKGROUND: Onychomycosis caused by F. solani are difficult to treat since this fungus presents high levels of resistance against commonly prescribed antifungal agents. OBJECTIVE: To evaluate the in vitro activity of itraconazole, terbinafine, ciclopirox and amorolfine against clinical isolates of F. solani. MATERIAL AND METHOD: A study was done in which the in vitro susceptibility of 29 clinical isolates of F. solani was determined using the microdilution method M38-A, as described by the Clinical Laboratory Standards Institute. The final dilutions were: 0.03-16 μg/mL for itraconazole, 0.13-64 μg/mL for terbinafine and amorolfine and 0.06-32 μg/mL for ciclopirox. RESULTS: The MIC50 and MIC90 for itraconazole were ≥16 μg/mL and ≥16 μg/mL, for terbinafine ≥64 μg/mL and ≥64 μg/mL, for amorolfine 1.25 μg/mL and ≥64 μg/mL and for ciclopirox 16 μg/mL and 20 μg/mL, respectively. CONCLUSIONS: Amorolfine exhibited the highest antifungal activity against clinical isolates of F. solani. [ABSTRACT FROM AUTHOR]

Copyright of Revista Iberoamericana de Micologia is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)